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Abstract 
Over the last two decades, several genes have been identified that appear to play a role 
in the regulation of energy homeostasis and body weight. For a small subset of them, a 
reduction or an absence of expression confers a resistance to the development of obesity. 
Recently, a knockin mouse for a member of the monocarboxylate transporter family, MCT1, 
was demonstrated to exhibit a typical phenotype of resistance to diet-induced obesity and a 
protection from its associated metabolic perturbations. Such findings point out at 
monocarboxylate transporters as putatively new therapeutic targets in the context of obesity. 
Here we will review what is known about monocarboxylate transporters and their possible 
metabolic roles in different organs and tissues. Based on the description of the phenotype of 
the MCT1 knockin mouse, we will also provide some insights about their putative roles in 
weight gain regulation. 
Structural and functional characteristics of monocarboxylate transporter isoforms 
Monocarboxylate transporters belong to the SLC16A family of solute carriers that 
contains 14 members based on sequence honmology 1, 2. However, only 4 of them have been 
demonstrated by functional characterization to be true monocarboxylate transporters3-6. They 
are identified as MCT1 (SLC16A1), MCT2 (SLC16A7), MCT3 (SLC16A8) and MCT4 
(SLC16A3). Based on the structural studies performed on MCT1, it has been proposed that 
these four monocarboxylate transporters have 12 transmembrane domains with both 
intracellular N- and C- terminals1. They were also shown to require chaperone glycoproteins 
to be properly inserted in the plasma membrane. A protein named basigin (also known as 
CD147) was shown to be the partner protein of either MCT1, MCT3 or MCT47, 8. In contrast, 
embigin (also known as gp-70) was found to be necessary for proper MCT2 insertion and 
function7, 9. 
All four monocarboxylate transporters are proton-dependent facilitative carriers10. They 
exhibit different selectivity and affinity for their substrates (see table I). MCT1 has the 
broadest selectivity and can transport several natural short-chain fatty acids such as acetate, 
butyrate, propionate, lactate or pyruvate. It also transports the ketone bodies acetoacetate and 
β-hydroxybutyrate. MCT2 has a much higher affinity for pyruvate although it also transports 
lactate and ketone bodies. MCT4 was shown to transport lactate and ketone bodies but to have 
a very low affinity for pyruvate. Informations are more restricted concerning MCT3 but it is 
clearly a lactate transporter. Overall, if we consider lactate as substrate, the highest affinity is 
exhibited by MCT2. In contrast, MCT4 has the lowest affinity for lactate but a very high 
transport capacity. These kinetic characteristics are in accordance with a major role for MCT4 
in lactate efflux from glycolytic tissues while MCT2 should be implicated in 
monocarboxylate uptake within cells which use these substrates either as oxidative fuels or for 
biosynthesis purposes. MCT1 (and to a lower extent MCT3 as this isoform has a very limited 
tissue distribution) seems to be used for both efflux and influx of monocarboxylates. 
The expression of each monocarboxylate transporter varies among the different tissues 
and organs (see table I). MCT1 has the largest distribution among all the monocarboxylate 
transporters and is considered ubiquitous. Thus, it is prominently (although not exclusively) 
expressed in brain, muscle, heart, liver, kidney, intestine, white adipose tissue, red blood cells, 
testis or placenta. At the cellular level, it can be found in several and/or distinct cell types 
within the same organ or tissue. For example in brain, it is found in astrocytes, endothelial 
cells, oligodendrocytes, ependymocytes, activated microglial cells and in at least some 
hypothalamic neurons. In striated muscle, it is abundant in oxidative (red, slow twitch) fibers 
but not in glycolytic (white, fast twitch) fibers. One cell type where it is conspicuously absent 
is the β cell of the pancreas. It has been shown that MCT1 expression in this cell type is under 
strict repression and a mutation in the promoter of MCT1 leads to a specific disease in 
humans that causes inappropriate insulin secretion triggered by blood lactate during exercise 
bouts11. MCT2 has a more restricted distribution than MCT1. Indeed, it has been found to be 
present in brain, kidney, liver and testis. Moreover, it was found to be the main 
monocarboxylate transporter in neurons throughout the brain12. In testis, it is present on the 
tail of elongating spermatids13. MCT3 is expressed in only one cell type in the body, the 
retinal pigmented epithelium14. Finally, MCT4 is found in brain, muscle and white blood 
cells. While in brain it is found exclusively on astrocytes15, 16, in muscle it is expressed only 
by glycolytic fibers17. 
Energetic roles of monocarboxylate transporters in different tissues 
Despite the fact that substantial progress has been made in recent years on the 
description and characterization of monocarboxylate transporters (for review, see1, 10), their 
specific involvement in energy homeostasis (together with the use of monocarboxylates as 
energy substrates) remains incompletely understood. An increasing number of studies have 
provided evidence demonstrating or at least suggesting an important role for 
monocarboxylates, and consequently for their transporters, in various organs and tissues. 
Moreover, several studies have documented specific regulations for each major 
monocarboxylate transporter in different tissues and cell types. Regulation of expression at 
both transcriptional and translational levels has been described, as well as modifications in 
subcellular distribution. In order to eventually understand the possible roles played by these 
transporters in the overall body energy homeostasis, it is important to review what is known 
in a few key organs and tissues in which they have been studied. 
Brain 
A cell-specific distribution of the three major monocarboxylate transporters has been 
found in the central nervous system. The fact that the high affinity transporter MCT2 is the 
predominant neuronal monocarboxylate transporter while MCT1 and MCT4 are rather found 
on glial cells has been used as an indication of a potential lactate shuttling mechanism 
between these different cell types. Indeed, several evidence indicate that astrocytes, which 
express the low affinity, high capacity monocarboxylate transporter MCT4 associated with 
highly glycolytic cells, provide lactate to neurons in an activity-dependent manner. Such a 
mechanism, called the Astrocyte-Neuron Lactate Shuttle, would sustain neuronal energy 
needs during periods of high activity18, 19. Interestingly, a similar mechanism has been 
proposed to take place between oligodendrocytes (which express MCT1) and axons20.  
Specific regulations in the expression of these transporters in each cell type have 
started to be uncovered. Thus, it has been shown that a series of neuroactive substances 
including noradrenaline, brain-derived neurotrophic factor (BDNF), Insulin-like growth 
factor-1 (IGF-1) and insulin cause a translationally-dependent upregulation of MCT2 
expression in neurons21-25. In addition, it was shown that MCT2 is distributed between a 
cytoplasmic, vesicular pool and a plasma membrane pool26. Such a subcellular localization of 
MCT2 in neurons can be modified. Thus, while stimulation with glutamate and glycine or 
TNF were shown to enhance the accumulation of MCT2 at the plasma membrane, exposure to 
AMPA or insulin was shown to reduce the cell surface expression27. In astrocytes, it was 
observed that both nitric oxide and oxygen tension can regulate in a transcriptional manner 
the expression of MCT428-30. These data suggest that MCT expression in different brain cell 
types are subject to regulation by various signals, which could affect brain energy 
homeostasis, as well as cognitive functions. Indeed, it was shown that interfering with 
cerebral monocarboxylate transporter expression can impair learning and memory 
formation31. Moreover, alterations in MCT expression could contribute to the etiology of 
various neurodegenerative diseases including amyotrophic lateral sclerosis20 and multiple 
sclerosis32. 
The brain is central in the maintenance and regulation of body energy homeostasis. 
Apart from their direct role in brain energetics, monocarboxylate transporters could also be 
involved in various key processes for body energy homeostasis including fuel sensing. 
Indeed, all three isoforms normally expressed in the brain have been shown to be 
overexpressed during high fat diet induced obesity and chronic hyperglycemia33, 34. This 
regulation underlines a specific sensitivity to the metabolic status, and a potential role for 
monocarboxylates and their carriers in the control of metabolism. In accordance with this 
point of view, the key metabolic hormone insulin was shown to stimulate the expression of 
the specific neuronal MCT2 isoform in cultured neurons23. Such a result suggests an 
important role of the MCTs and their substrates in the metabolic actions of insulin. Insulin is 
one of the most important endocrine signals involved in energy homeostasis regulation. 
Supporting the possibility of an interaction between monocarboxylates and insulin, Park et al. 
have described a beneficial role of ketone bodies in type 2 diabetes. Indeed, they showed that 
hypothalamic infusion of ketone bodies improved leptin and insulin sensitivity of the brain in 
diabetic rats. Moreover, this action led to a decreased body weight and modified glucose 
metabolism35. 
All these studies demonstrate that variations in the peripheral metabolic status can 
alter the expression level of the MCTs in the brain, suggesting that cerebral monocarboxylate 
supply is altered as well. Several studies have explored the putative involvement of these 
monocarboxylates in the control of body energy homeostasis via a central effect. Among 
these, lactate is probably the most studied. Lactate was shown to play a role in the activation 
of the well-known glucose-sensitive neurons of the hypothalamus36. Using an 
electrophysiological approach, it has shown that lactate reversed the inhibitory effect of a 
decreased glucose concentration on glucose-excited neurons. However, lactate increased the 
activity of the glucose-inhibited neurons (the opposite effect than with glucose)36. Moreover, 
as indicated by the same group, these opposite effects of lactate on glucose-inhibited and 
glucose-excited neurons suggest an involvement of lactate in hypoglycemia regulation37. As 
proposed in the Astrocyte Neuron Lactate Shuttle (ANLS) model 18, a predominant glycolytic 
metabolism in astrocyte seems to play a key role in cerebral energy homeostasis regulation 
via monocarboxylate supply to neurons. Accordingly, the end product of glycolysis pyruvate 
has been demonstrated to be key in the brain control of glucose production38. In this study, 
lactate produced by astrocytes was suggested to be taken up by neurons and converted into 
pyruvate which in turn enters into oxidative neuronal metabolism. Finally, such pyruvate 
metabolism activates neuronal populations that leads to a decreased glucose production in 
peripheral organs38. In parallel, several studies have demonstrated that central exposure to 
lactate suppresses food intake and stimulates pancreatic insulin secretion, suggesting its 
involvement in the sensing of increased energy supply39-41. Lactate signaling involves 
neuronal responses, and most likely involves at least in part glucose metabolism in astrocytes, 
producing such lactate which is then transferred to neurons. In accordance with this 
hypothesis, recent results demonstrate that astroglial connexins are required for hypothalamic 
glucose sensing, suggesting that astrocyte glucose metabolism is needed for centrally 
mediated glucose-induced insulin secretion as well as food intake suppression42. 
In addition to situations of increased energetic supply such as hyperglycemia or 
obesity, hypoglycemia was also described as a condition that involves monocarboxylates as 
alternative energetic substrates for the brain. Thus, studies have demonstrated that 
hypoglycemia is associated with increased brain MCT expression in order to favor the use of 
these alternative energetic substrates. Moreover, this overexpression is associated with 
increased monocarboxylate uptake (mainly lactate and acetate) during hypoglycemic events in 
type 1 diabetic subjects43, 44. Furthermore, brain regions sensitive to hypoglycemia, e.g. the 
dorsal vagal complex, contain a neuronal population called A2 neurons that express genes 
encoding metabolic transducers. These neurons are sensitive to insulin-induced hypoglycemia 
which also decreases MCT2 levels, in parallel to increase glucose transporter and glucokinase 
expression. Finally, lactate infusion in this brain area reversed the insulin–induced 
hypoglycemia-mediated reduction of MCT2 expression and increase of GLUT3 expression45. 
Such results have been observed in both hypothalamus and dorsal vagal complex, two regions 
implicated in glucose and energy homeostasis regulation46-48. Furthermore, inhibition of 
monocarboxylate transporters in these specific brain metabolic-sensitive regions is associated 
with a defect of energy deficiency counter-regulatory responses49, 50. Finally, a study has 
demonstrated that blockade of monocarboxylate transporters in the dorsal vagal complex 
resulted in dose-dependent increases in glycemia, demonstrating the importance of 
monocarboxylate transport at least in glucose homeostasis51. 
Quite interestingly, a mechanism related to ANLS is suggested to be involved in the 
activation of hypothalamic glucose responsive (GR) neurons. Indeed, using adenoviral-driven 
expression of recombinant targeted luciferases and bioluminescence imaging, Ainscow et al. 
demonstrated that GR neurons are not sensitive to increased glucose concentrations. In 
contrast, hypothalamic glial cells responded to glucose with an increased intracellular ATP 
concentration. In addition, these cells also responded to increased lactate concentrations and 
the same cells were also associated with a high level of MCT1 transporter expression. 
Altogether, these results suggest that stimulation of hypothalamic neurons by glucose may be 
potentiated in vivo by the release of lactate from glial cells52. Moreover, other studies on NPY 
and POMC hypothalamic neurons showed that maternal obesity is associated with a loss of 
the NPY neuron response to hyperglycemia. Also, the authors described in the hypothalamus 
a lower glucose uptake and lactate release. Finally, glucose exposure induced a decrease of 
GLUT1 and MCTs levels, as well as of lactate dehydrogenase B (LDHB), NPY and POMC 
levels in offsprings exposed to maternal obesity. In the same study, the authors have also 
examined the same markers in postnatal HFD models and described a decreased lactate 
release associated with a decreased neuronal MCT2 isoform, but increased POMC mRNA 
levels in response to a glucose challenge. In both case (maternal obesity or postnatal HFD), 
lactate transport and MCTs levels are associated with a deregulated POMC or NPY neuronal 
response, thus leading to altered energy homeostasis 53. This study is in accordance with 
others and contributes to highlight the main role of lactate and monocarboxylate transporters 
in brain control of energy homeostasis. Along the same lines, Cortes-Campo et al. recently 
demonstrated the presence of the MCT2 isoform in the hypothalamus in 90% of orexigenic 
AgRP neurons and in 60% of anorexigenic POMC neurons. They also showed its role in 
lactate uptake by hypothalamic neurons suggesting that these neurons control food intake by 
detecting lactate changes which reflect glucose levels54. Finally, a recent work showed that 
fatty acid-induced food intake inhibition seems to depend on astrocytic metabolism. Thus, 
fatty acid metabolism in astrocytes induced an increased ketone bodies production correlated 
with a decreased food intake as the inhibition of ketogenesis reverse the fatty acid effect55. 
Accordingly, a ketogenic diet-induced weight loss is associated with alteration of circulating 
hormones and nutrients involved in appetite control. Among these, insulin, leptin and glucose 
levels decreased as well as non-esterified fatty acid levels. All of them are commonly 
implicated in energy homeostasis regulation56. In addition, Konig et al. have demonstrated 
that fasting (a well-known state in which ketonemia increases) activates PPARα which in turn 
increases liver, kidney and small intestine MCT1 mRNA levels57. As PPARα is involved in 
obesity, this result is in accordance with previous work from our group showing an increased 
expression of MCTs in brain during high fat diet-induced obesity34. Recent studies have 
shown that ketone bodies influence AgRP orexigenic neuropeptide expression in cultured 
cells and in vivo in a type 1 diabetes model58, 59. Thus, brain ketone bodies could be in some 
circumstances, an orexigenic signal.  
Altogether, these results strongly suggest that monocarboxylates are involved in brain 
control of food intake. Thus, MCTs and their level of expression in various cell types might 
be key players of centrally controlled body energy homeostasis regulation. 
Muscle 
Peripheral organs or tissues involved in the control of energy homeostasis are also 
known to present a metabolic sensitivity to monocarboxylates. Muscles are certainly a 
predominant source as well as users of monocarboxylates. Indeed, some forms of exercise are 
well known to induce an increase of glycolytic activity in certain muscle fiber types causing a 
large release of lactate. This lactate can in turn be recycled in part within the muscle itself, 
since surrounding oxidative muscle fibers will use it as an additional oxidative energy 
substrate 60. In such case, lactate metabolism involves distinct MCT isoforms differentially 
expressed on muscle fibers17. However, still few studies have investigated the role of muscle 
monocarboxylate transporters in the maintenance of the body energy homeostasis balance. 
Muscle is implicated in glucose homeostasis and in insulin resistance. An interesting study 
has looked at the possible link between lactate transport and the known beneficial effects of 
food restriction61. Indeed, food restriction is known to increase insulin sensitivity but the 
mechanisms are not fully understood. However, in this study the authors provided evidence 
that food restriction reduces muscle lactate content as well as glycogen content. Such reduced 
intracellular lactate is accompanied by an increased lactatemia. Altogether, the authors 
described an increased lactate transport capacity in the muscle even without altered MCT1 or 
MCT4 expression61. Such results suggesting a beneficial role of lactate production during 
obesity or diabetes at least in part explains the improved insulin sensitivity observed during 
food restriction. Moreover, it has been reported that maternal obesity is associated in 
offsprings with increased body weight, insulin and lactate concentrations, and reduced 
GLUT4 as well as increased MCT1 levels in muscle62. Moreover, these dams from obese 
mothers are more sensitive to obesity development. So, the increased lactate and MCT1 levels 
suggesting an increased lactate transport might be in part associated with the metabolic 
disease sensitization. On the opposite, obese subjects which present an increased MCT4 
protein level in muscle compared to lean subjects exhibited decreased MCT4 levels down to 
the lean control level when submitted to a weight loss63. Concerning MCT1, this study did not 
describe any change in muscle expression after weight loss. However, it has been described 
that this isoform is preferentially found in oxidative fibers. Moreover, several studies 
described modifications in MCT1 expression levels during obesity depending on changes in 
oxidative parameters and adipose tissue content64-66. In skeletal muscle, two monocarboxylate 
transporters have been mainly described: MCT1 and MCT4, and both are involved in pH and 
lactate regulation. Moreover, exercise has been shown to modify the expression level of these 
two isoforms in sarcolemmal membranes suggesting an adaptation as a function of the 
energetic needs. Finally, MCT1 and MCT4 are differentially regulated by exercise. MCT1 
exhibited greater increases in expression than MCT4 after acute exercise, but both are 
increased to similar extent during chronic exercise. Such regulations seem to be correlated to 
modifications in energy needs, and alterations in MCTs levels are considered as an important 
adaptation to increased energy demands demonstrating their sensitivity to energy 
requirements in muscle67. Interestingly, Huber et al. also demonstrated an increase in 
expression of MCTs in muscles of offsprings after an intra-uterine growth restriction and 
moderate daily exercise68. They described changes in muscle structure and metabolic function 
in part due to increased MCTs levels. This increased MCTs expression allowed to prevent 
exercise-induced lactate accumulation in the offsprings. Thus muscle contractility is 
facilitated and allows the newborn to better support exercise and prevent obesity 
development68. Moreover, in the insulin-resistant zucker rat model, a decreased lactate influx 
in skeletal muscles was accompanied by a decreased expression of the transporters MCT1 and 
MCT4. In addition, the authors also showed a redistribution of the LDH isozymes which is 
fiber specific. The localization of LDH5 was found to be related to MCT1 only in obese 
animals, which came as a surprise since LDH5 is more related to glycolysis than oxidative 
metabolism69. Finally, as an inverse correlation exists between plasma lactate and insulin 
sensitivity70, these results suggest a role in lactate transport and muscle metabolism that can 
be linked to insulin sensitivity. Interestingly, ketone bodies are also described to inhibit 
insulin-induced glucose uptake in oxidative muscles but not in glycolytic ones by inhibiting 
insulin signaling71. Such a result suggests that ketone bodies could also alter muscle energy 
homeostasis.  
Adipose tissue 
Adipose tissue is another key player in the control of body energy homeostasis. In 
addition, lactate production by adipose tissue is described as depending on nutritional state72, 
73. Moreover, it has been known for decades that a correlation exists between fat cell size and 
conversion of glucose into lactate. In fact, by producing lactate adipose tissue seems to 
provide lactate to liver as a substrate for gluconeogenesis during fasting or for glycogen 
synthesis after a meal. In the case of obesity, lactate production by the adipose tissue is 
increased. Moreover, this overproduction is also correlated with insulin resistance 74. 
Altogether, it appears that lactate production is important in adipose tissue metabolism. 
Moreover, it suggests an important role of MCTs in adipose tissue contribution to energy 
homeostasis. In human adipocytes, MCT1, 2 and 4 mRNAs are expressed, and in mice, 
MCT1 was described in both brown and white adipose tissue75-77. Of particular interest, a 
recent study showed that hypoxia induced an increase in MCT1 and 4 mRNA expression but 
decreased MCT2 mRNA expression in adipocytes finally leading to an increased production 
of lactate. The authors suggest that this could be an adaptive mechanism to low O2 tension as 
adipose tissue expands during obesity development76. Another group has shown a decrease of 
MCT1 levels in adipocytes from diabetic rats. Such a decrease in transporter expression is 
associated with a fall in lactate transport, thus confirming an important role of lactate 
transport and metabolism in adipose tissue and energy homeostasis as this lactate lifespan is a 
key element in glucose homeostasis78. In parallel, it was demonstrated that a ketone ester 
feeding induced hyperketonemia activates heat production in mice, in part by increasing the 
formation of brown adipose tissue. Interestingly, it was also demonstrated to decrease brain 
malonylCoA, an important determinant of appetite and described to be beneficial against 
obesity. Finally, ketones appear to be able to mimic the metabolic action of insulin and can be 
used to overcome the effects of insulin resistance79. These actions in relation with adipose 
tissue roles in body energy homeostasis likely require the presence of monocarboxylate 
transporters. 
Liver 
Hepatocytes express both the MCT1 and the MCT2 isoforms. MCT1 in the liver has been 
shown to be a key player in lipid and glucose homeostasis, as it has been demonstrated that 
agonists of PPARα (which mediates the adaptive response to fasting and upregulates MCT1) 
such as oxidized fat and linoleic acid increase the level of MCT1 expression in the liver of 
both rodents and pigs. Moreover, the authors described an upregulation of CD147 which is 
required for the translocation and transport of MCT1 to the plasma membrane8, 80. These 
results indicate that MCT1 is involved in the adaptation to the fasting state. In addition, 
researchers have shown parallel changes in glucagon and insulin sensitivity associated with 
increased MCT1 and decreased MCT2 levels in liver in undernutrition conditions. Such 
modifications could be interpreted as an adaptation to food restriction, allowing cells to 
maintain a normal activity by the use of alternative substrates such as ketone bodies whose 
concentration increases in such conditions81. Moreover, liver is one of the main sites of 
neoglucogenesis, an important mechanism involved in response to fasting and in metabolic 
regulations. Such a mechanism involves in part lactate via its conversion to pyruvate, and thus 
lactate uptake via monocarboxylate transporters on hepatocytes would be critical to sustain 
such a process. Moreover, ketone bodies have also been described to prevent the nuclear 
localization of ChREBP, the glucose responsive transcription factor involved in lipid 
synthesis in liver, thus inhibiting fat synthesis in liver. This demonstrates a role of ketone 
bodies in energy homeostasis regulation82. Thus, monocarboxylate transporters might be 
important elements regulating the involvement of the liver in the regulation of body energy 
homeostasis. 
Intestine 
In the intestine, the role of MCT1 has been mostly associated with the absorption of short-
chain fatty acids (SCFAs). SCFAs were shown to induce an upregulation of MCT1 expression 
and function83-85. In fact, SCFAs seem to modulate the localization of MCT1 on the apical 
membrane facilitating the transport of SCFAs themselves86. The intestinal localization and 
abundance of MCT1 expression has been well described, notably in pigs87. This study 
revealed a higher expression in the large intestine than in the small intestine. In addition, if 
MCT1 is localized in immune cells and lamina propria in the small intestine, this transporter 
is mainly found on epithelial cells in the colon87. However, even if some recent papers have 
described the presence and regulation of MCT1 in the intestine of various species including 
man88-92, little is known about its specific involvement in nutrient absorption for instance. 
Nevertheless, some studies suggest that butyrate which is transported in the colon by MCT1 
serves as a substrate for de novo lipogenesis, and that SCFAs downregulate genes involved in 
cholesterol synthesis,  suggesting a role of the intestinal MCT1 in lipid metabolism 93, 94. 
Moreover, obesity is associated with an increase in colon permeability to lipopolysaccharide 
(LPS). This process seems to be sensitive to acetoacetate, a ketone body transported by 
MCT1. In fact, LPS permeability of the colon seems to be due to lipid peroxidation. Thus, 
addition of antioxidants like vitamin E inhibits this permeability. Finally, as acetoacetate 
inhibits high peroxide production, a succinate dependent mechanism, they can act as an 
antioxidant and thus, prevent LPS permeability (see review of Alexandre95). Thus, intestinal 
MCT1 is likely to be an important factor in different physiological and pathophysiological 
situations affecting energy metabolism. 
Pancreas 
Monocarboxylates and their transporters are also important for pancreas function, and in 
particular glucose-stimulated insulin secretion, a key event in maintaining glycaemia in the 
normal range. Indeed, the TCA cycle fueled by glucose-derived pyruvate is strongly involved 
in β-cell function by generating the intracellular messenger ATP, glutamate for mitochondrial 
metabolism and eventually the electron transfer chain ROS production involved in insulin 
secretion96-99. Potentially, the transport of pyruvate (as well as lactate) could be an important 
element in the regulation of β-cell insulin release. Under physiological conditions, MCTs and 
LDHs exhibit a low expression/activity in β-cells, a situation which contribute to prevent 
pyruvate from leaving the cell100. Interestingly, the low expression of MCTs in the plasma 
membrane of islet cell types seems to be an advantage for proper cell function, as 
overexpression of MCT activity confers insulin secretion sensitivity to lactate in islets whose 
insulin secretory capacity is lost101. Finally, congenital hyperinsulinism is also associated with 
an increased expression of MCT1. Such congenital hyperinsulinism is characterized by a 
deregulated secretion of insulin from β-cells and causes hyperinsulinemia and 
hypoglycemia102. Thus, a tight control over the expression of MCTs by β-cells must be 
exerted in order to ensure that they will maintain their critical role of glucose-dependent 
insulin suppliers. 
The proof-of-concept: resistance to diet-induced obesity of the MCT1 knockin mouse 
As highlighted above, the MCT1 isoform is found in several tissues including the 
brain, muscle, liver adipose tissue and the intestine, all involved in energy homeostasis 
regulations 103. Moreover, all these tissues are known to exhibit either high monocarboxylate 
utilization (e.g. lactate or pyruvate) or lactate production for instance. It is however difficult to 
predict what could be the overall impact of altered MCT1 expression/activity in these 
different tissues and organs on body energy homeostasis. In this regard, transgenic animals 
are extremely useful tools to provide an integrated view of the particular role of a specific 
protein. Recently, a knockin mouse for the mct1 gene was produced and its phenotype was 
characterized 75.  
The strategy used was to disrupt the mct1 gene by replacing part of the coding 
sequence by the LacZ gene coding for the bacterial enzyme β-galactosidase placed in frame 
with the mct1 promoter. This approach had the advantage of creating a reporter gene for 
MCT1 expression while invalidating the original gene. Expression of the reporter gene could 
also be used to confirm the success of the invalidation and the presence of the modified allele 
in a particular tissue. The first interesting information emerging from the generation of this 
transgenic mouse is the fact that the null mutant (homozygote carrying both mutated alleles or 
MCT1-/-) was not viable. Indeed, it seems that the embryonic development was halted quite 
early on as both homozygote newborns and embryos were never observed. Although it is 
quite difficult at this stage to provide a precise explanation for this lethal phenotype, it points 
out at the importance of monocarboxylates for early development. It is important to underline 
the fact that MCT1 expression is high in the placenta 104, and the lack of its expression in this 
tissue might have played a critical in the embryonic development of null mutants. 
In contrast to homozygotes, heterozygotes for the invalidated mct1 allele (MCT1+/-) 
survived and lived normally throughout adulthood. Indeed, no effect on longevity or survival 
rate was noted for these animals. Extensive investigations at the morphological, histological 
and behavioral levels did not uncover major differences nor deficits compared to wildtype 
animals (MCT1+/+). Apart from a small but significant difference in length (MCT1+/- are 
shorter than MCT1+/+), heterozygotes are indistinguishable from wildtype animals (see Figure 
1). It is important to mention that as a consequence of the partial invalidation, MCT1 
expression at both the mRNA and protein levels is variably affected from one tissue to 
another. In some cases it is reduced by up to 50% (e.g. brain) while in others it is marginally 
affected (e.g. adipose tissue or liver).  
However, the most striking change took place when mice were fed a high sugar, high 
fat diet for several weeks. Under such conditions, wildtype C57BL/6 mice gained weight and 
became obese as this strain is known to be particularly sensitive to diet-induced obesity. In 
contrast, MCT1+/- mice fed a similar high sugar, high fat diet resisted to the development of 
obesity, an effect observed in male75 as well as in female mice (Figure 1). Such a phenotype 
could be explained by modifications of energy intake and/or energy expenditure. Indeed, it 
was found that MCT1+/- mice exhibited a reduced food intake compared to wildtype animals, 
but only when exposed to a high sugar, high fat diet. As mentioned earlier, MCT1 was shown 
previously to be expressed by some populations of hypothalamic neurons and suggested to 
play a role in nutrient sensing 52. Moreover, a mutant of the MCT1 ortholog was produced in 
Drosophila and called Silnoon 105. Interestingly, this mutant exhibited halted food intake, 
reinforcing the view that MCT1 expression is critical for the regulation of food intake. In 
addition to food intake, intestinal nutrient absorption by MCT+/- mice was clearly reduced 
compared to MCT1+/+ mice as the caloric content of their stool was higher. Concerning 
energy expenditures, although no significant difference in physical activity could be detected 
between the two genotypes, MCT1+/- mice had a higher basal metabolism specifically during 
their resting (diurnal) period, as revealed by a higher O2 consumption and CO2 production, 
but only when fed a high sugar, high fat diet. The respiratory quotient however was similar 
between the two genotypes, indicating that there was no shift in the use of carbohydrates and 
lipids. 
When body composition was examined, it became clear that MCT1+/- mice had a 
reduced fat mass compared to MCT1+/+ mice. Further histological analysis revealed that some 
but not all white adipose tissues were reduced in size. For example, it was the case for the 
subcutaneous and perigonadal but not the inguinal adipose tissue. The main factor apparently 
contributing to the reduced adipose tissue mass appeared to be the size of the adipocytes, 
suggesting a reduced capacity to accumulate and store lipids. In parallel, a clear reduction in 
the size and appearance of the liver was evidenced (Figure 2). Indeed, the liver of MCT+/- 
mice was smaller and of a dark red color compared to the bigger and pink liver of MCT1+/+ 
mice. An histological analysis confirmed that while the liver of MCT1+/+ mice was full of 
lipid droplets, a clear sign of hepatic steatosis, the liver of MCT+/- mice was free of any lipid 
deposition. Interestingly, exposure to a high sugar, high fat diet led to an enhancement in the 
hepatic MCT1 expression of MCT1+/+ mice. This effect was blunted in the liver of MCT+/- 
mice. Similarly, several genes involved in either lipid synthesis, transport, release, storage or 
oxidation, as well as transcription factors regulating the expression of these genes, have seen 
their enhanced hepatic expression induced by exposure to the diet to be prevented in the liver 
of MCT+/- mice. Thus, it appears that hepatic lipid metabolism has become impervious to 
dietary changes in MCT+/- mice. 
In addition to reduced weight gain by limited increase in fat mass and protection from 
hepatic steatosis, MCT+/- mice did not exhibited the usual glucose intolerance and insulin 
resistance that normally arise following exposure to high sugar, high fat diet. Moreover, both 
insulinemia and leptinemia remained in the normal range for MCT+/- mice compared to 
MCT+/+ mice. Thus, the haploinsufficiency for the mct1 gene has important metabolic 
consequences relevant for energy homeostasis. It clearly modifies the way the organism 
handles a diet rich in both sugars and lipids, offering some sort of protection from the 
deleterious aspects of such an obesogenic diet. However, the precise mechanisms by which 
MCT1 is involved in these different effects remain to be established. 
Conclusion 
 Over the years, several genes have been identified which appear to play a critical role 
in body weight control. This is the case notably for the genes encoding the hormone leptin and 
its receptor. Mutations or invalidation of these genes generally lead to an obese phenotype. 
There exists however a small group of genes for which invalidation rather confers a resistance 
to the development of diet-induced obesity. Such genes encode proteins belonging to different 
categories including for example enzymes involved in lipid metabolism or neuropeptides. 
With the monocarboxylate transporter MCT1, a new category of nutrient transporters can be 
added to the list. However, more work is needed to clarify the exact role of MCT1 in each 
organ and tissue in which it is expressed to the integrated regulation of body energy 
homeostasis. Although some clues have emerged concerning its involvement in food uptake 
regulation and intestinal lipid metabolism, much remains to be done for several organs (e.g. 
liver, muscle or adipose tissue) and/or distinct functions (e.g. basal metabolism). Moreover, 
the role of the other MCT family members has not been explored yet and would certainly 
deserve further attention in the near future.  
Considering their distribution and their suggested functions in various aspects of 
metabolism, it is likely that their expression both in the central nervous system and in the 
periphery might be influenced by nutritional manipulations including caloric restriction and 
refeeding. Although nothing has been published so far in this direction, it is tempting to 
speculate that monocarboxylate transporters might play a key role in the adaptations taking 
place during weight loss and upon weight regain. Further investigations of these questions 
would certainly benefit in the near future from the generation of transgenic mice allowing to 
produce tissue-specific invalidated animals for one or the other monocarboxylate transporter. 
With these animals in hand, it would become very interesting to explore in more details the 
role of monocarboxylate transporters in dieting and weight regain. 
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Table I. The four most studied monocarboxylate transporters and their main characteristics 
Name Gene Main substrates Substrate affinity 
(Km in mM) 
Tissue 
distribution/cellular 
localization 
MCT1 SLC16A1 Lactate, 
pyruvate, ketone 
bodies, acetate, 
butyrate, 
propionate 
3.5 (Lactate) 
1.0 (Pyruvate) 
10.1 (BHB) 
5.5 (AcAc) 
Ubiquitous: Muscle 
(red fiber), heart, 
liver, adipose tissue 
(white), intestine, 
red blood cells, 
placenta, brain 
(astrocytes 
endothelial cells, 
oligodendrocytes, 
ependymocytes, 
activated microglia, 
some hypothalamic 
neurons), etc 
MCT2 SLC16A7 Pyruvate, lactate, 
ketone bodies 
0.08 (Pyruvate) 
0.74 (Lactate) 
1.2 (BHB) 
0.8 (AcAc) 
Brain (neurons), 
liver, kidney, 
spermatogonia 
MCT3 SLC16A8 Lactate 6.0 (Lactate) Retinal pigment 
epithelium 
MCT4 SLC16A3 Lactate, ketone 
bodies 
28 (Lactate) 
130 (BHB) 
216 (AcAc) 
Muscle (white 
fiber), brain 
(astrocytes), white 
blood cells 
 
  
Figure legends 
Figure 1. Photographs of representative MCT1+/+ and MCT1+/- female mice fed either a 
normal chow diet (left panel) or a high sugar high fat diet for 12 months (right panel). 
Figure 2. Photograph of the liver from a MCT1+/+ mouse (left panel) or a MCT1+/- mouse 
(right panel) fed a high sugar high fat diet for 3 months. Notice the difference in size 
(MCT1+/+ >> MCT1+/-) and in color (pink vs. dark red). 
 


